MX2019004200A - Terapia de combinacion. - Google Patents

Terapia de combinacion.

Info

Publication number
MX2019004200A
MX2019004200A MX2019004200A MX2019004200A MX2019004200A MX 2019004200 A MX2019004200 A MX 2019004200A MX 2019004200 A MX2019004200 A MX 2019004200A MX 2019004200 A MX2019004200 A MX 2019004200A MX 2019004200 A MX2019004200 A MX 2019004200A
Authority
MX
Mexico
Prior art keywords
antibody
combination therapy
effective amount
combination
he8l
Prior art date
Application number
MX2019004200A
Other languages
English (en)
Inventor
James Mergott Dustin
Andrew Willis Brian
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2019004200A publication Critical patent/MX2019004200A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona un método para tratar una enfermedad cognitiva o neurodegenerativa, que comprende administrar a un paciente que necesita tal tratamiento una cantidad efectiva de un compuesto de la fórmula I: o su sal farmacéuticamente aceptable en combinación con una cantidad efectiva de un anticuerpo anti-N3pGIu Abeta seleccionado del grupo que consiste de hE8L, B12L, R17L, anticuerpo I y anticuerpo II. (ver Fórmula).
MX2019004200A 2016-10-21 2017-10-13 Terapia de combinacion. MX2019004200A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662410997P 2016-10-21 2016-10-21
PCT/US2017/056451 WO2018075339A1 (en) 2016-10-21 2017-10-13 Combination therapy

Publications (1)

Publication Number Publication Date
MX2019004200A true MX2019004200A (es) 2019-08-05

Family

ID=60320983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004200A MX2019004200A (es) 2016-10-21 2017-10-13 Terapia de combinacion.

Country Status (13)

Country Link
US (1) US20190231791A1 (es)
EP (1) EP3528844A1 (es)
KR (1) KR20190055163A (es)
CN (1) CN109843326A (es)
AR (1) AR110470A1 (es)
AU (1) AU2017345141A1 (es)
BR (1) BR112019005217A2 (es)
CA (1) CA3038715A1 (es)
EA (1) EA201990559A1 (es)
IL (1) IL265340A (es)
MX (1) MX2019004200A (es)
TW (1) TWI669119B (es)
WO (1) WO2018075339A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
US20220177560A1 (en) 2019-03-26 2022-06-09 Janssen Pharmaceutica Nv Antibodies to Pyroglutamate Amyloid-B and Uses Thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045218A1 (es) 2003-08-08 2005-10-19 Schering Corp Aminas ciclicas inhibidoras de bace-1 que poseen una benzamida sustituyente; composiciones farmaceuticas que las contienen y su uso en la fabricacion de medicamentos para tratar enfermedades cognitivas o neurodegenerativas.
US20100317850A1 (en) 2008-01-18 2010-12-16 Yuichi Suzuki Condensed aminodihydrothiazine derivative
LT3042917T (lt) * 2010-08-12 2018-05-10 Eli Lilly And Company Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas
GB201101139D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
AR104241A1 (es) * 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos

Also Published As

Publication number Publication date
AU2017345141A1 (en) 2019-04-04
EP3528844A1 (en) 2019-08-28
TW201827055A (zh) 2018-08-01
US20190231791A1 (en) 2019-08-01
CN109843326A (zh) 2019-06-04
AR110470A1 (es) 2019-04-03
KR20190055163A (ko) 2019-05-22
EA201990559A1 (ru) 2019-08-30
TWI669119B (zh) 2019-08-21
IL265340A (en) 2019-05-30
CA3038715A1 (en) 2018-04-26
BR112019005217A2 (pt) 2019-07-02
WO2018075339A1 (en) 2018-04-26

Similar Documents

Publication Publication Date Title
PH12017500493A1 (en) Combination therapy
MX2021000071A (es) Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
WO2018022668A3 (en) NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
SG10201810401RA (en) Pharmaceutical combinations for treating cancer
EA201590655A8 (ru) Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений
PH12016502352A1 (en) Pharmaceutical composition
MX2021006901A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
TW201613578A (en) Pharmaceutical combinations
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
EA201991688A1 (ru) Фармацевтические комбинации для лечения рака
EA035519B9 (ru) 1,3,4-тиадиазольные соединения и их применение в лечении рака
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
MX2019004200A (es) Terapia de combinacion.
MX2021014120A (es) Tratamiento de los sintomas asociados a terapia privacion de androgenos.
MX2018001684A (es) Metodo de curacion de heridas.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
MX2020001217A (es) Metodos de tratamiento de sintomas de gastroparesia usando velusetrag.
MX2021003204A (es) Compuesto que contiene oxadiazol y composicion farmaceutica que contiene el mismo.
EA201990712A1 (ru) Лечение рассеянного склероза посредством chs-131
TH168113A (th) อนุพันธ์เฮเทอโรไซคลิค